Abstract

Pulse oximetry (PO) screening is used to screen newborns for critical congenital heart defects (CCHD). Analyses performed in hospital settings suggest that PO screening is cost-effective. We assessed the costs and cost-effectiveness of PO screening in the Dutch perinatal care setting, with home births and early postnatal discharge, compared to a situation without PO screening. Data from a prospective accuracy study with 23,959 infants in the Netherlands were combined with a time and motion study and supplemented data. Costs and effects of the situations with and without PO screening were compared for a cohort of 100,000 newborns. Mean screening time per newborn was 4.9 min per measurement and 3.8 min for informing parents. The additional costs of screening were in total €14.71 per screened newborn (€11.00 personnel, €3.71 equipment costs). Total additional costs of screening and referral were €1,670,000 per 100,000 infants. This resulted in an incremental cost-effectiveness ratio of €139,000 per additional newborn with CCHD detected with PO, when compared to a situation without PO screening. A willingness-to-pay threshold of €20,000 per gained QALY for screening in the Netherlands makes the screening likely to be cost-effective.Conclusion: PO screening in the Dutch care setting is likely to be cost-effective.What is Known:• Pulse oximetry is increasingly implemented as a screening tool for critical congenital heart defects in newborns.• Previous studies suggest that the screening in cost-effective and in the USA a reduction in infant mortality from critical congenital heart defects was demonstrated.What is New:• This is the first cost-effectiveness analysis for pulse oximetry screening in a setting with screening after home births, with screening at two moments.• Costs of pulse oximetry screening in a setting with hospital and homebirth deliveries were €14.71 and is likely to be cost-effective accordint to Dutch standards.

Highlights

  • Pulse oximetry (PO) screening to detect critical congenital heart defects (CCHD) in newborns has been studied widely in the past years and was proven to be accurate, safe, easy, and acceptable in settings with delivery and screening in hospital [6, 12, 15, 23, 30]

  • Pulse oximetry is increasingly implemented as a screening tool for critical congenital heart defects in newborns

  • This is the first cost-effectiveness analysis for pulse oximetry screening in a setting with screening after home births, with screening at two moments

Read more

Summary

Introduction

Pulse oximetry (PO) screening to detect critical congenital heart defects (CCHD) in newborns has been studied widely in the past years and was proven to be accurate, safe, easy, and acceptable in settings with delivery and screening in hospital [6, 12, 15, 23, 30]. One quarter of all congenital heart defects are critical and require surgery or catheter intervention in the first month of life [9]. Diagnosis of these CCHD, before signs of cardiovascular collapse, is pivotal in reducing morbidity and mortality. PO can be added to the regular screening program (prenatal ultrasound and postnatal examination) in order to reduce the cases with late diagnoses. It is known that a timely diagnosis of CCHD improves the chances of a favorable outcome with less mortality and morbidity [3]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call